Chronic Viral Hepatitis Signifies the Association of Premixed Insulin Analogues with Liver Cancer Risks: A Nationwide Population-Based Study

Chien-Hsieh Chiang, Chia-Sheng Kuo, Wan-Wan Lin, Jun-Han Su, Jin- De Chen and Kuo-Chin Huang
Additional contact information
Chien-Hsieh Chiang: Department of Family Medicine, National Taiwan University Hospital & College of Medicine, Taipei 100, Taiwan
Chia-Sheng Kuo: Department of Community and Family Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei 108, Taiwan
Wan-Wan Lin: Graduate Institute of Pharmacology, National Taiwan University College of Medicine, Taipei 100, Taiwan
Jun-Han Su: Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA
Jin- De Chen: Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei 108, Taiwan
Kuo-Chin Huang: Department of Family Medicine, National Taiwan University Hospital & College of Medicine, Taipei 100, Taiwan

IJERPH, 2019, vol. 16, issue 12, 1-11

Abstract: This study sought to determine whether chronic hepatitis B or C would modify the association between insulin analogues and hepatocellular carcinoma (HCC) risks. We conducted a nationwide nested case-control study for HCC cases and matched controls from 2003 to 2013 among newly diagnosed type 2 diabetes patients on any antidiabetic agents in Taiwan before and after exclusion of chronic viral hepatitis, respectively. A total of 5832 and 1237 HCC cases were identified before and after exclusion of chronic viral hepatitis, respectively. Incident HCC risks were positively associated with any use of premixed insulin analogues (adjusted odds ratio (OR), 1.27; 95% CI 1.04 to 1.55) among total participants, especially among current users (adjusted OR, 1.45; 95% CI 1.12 to 1.89). However, the association between HCC occurrence and premixed insulin analogues diminished among participants without chronic viral hepatitis (adjusted OR, 1.35; 95% CI 0.92 to 1.98). We also observed a significant multiplicative interaction between chronic viral hepatitis and premixed insulin analogues on HCC risks ( P = 0.010). Conclusions: Chronic viral hepatitis signifies the role of premixed insulin analogues in HCC oncogenesis. We recommend a closer liver surveillance among patients prescribed premixed insulin analogues with concomitant chronic viral hepatitis.

Keywords: hepatocellular carcinoma; chronic hepatitis B; chronic hepatitis C; population-based study; type 2 diabetes mellitus (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/16/12/2097/pdf (application/pdf)
https://www.mdpi.com/1660-4601/16/12/2097/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:16:y:2019:i:12:p:2097-:d:239525

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().